Erasca, Inc.

Equities

ERAS

US29479A1088

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:30:00 01/06/2024 am IST			5-day change	1st Jan Change
2.54 ^USD	+2.42%		-3.42%	+19.25%

21/05	Erasca Closes Oversubscribed Share Offering to Raise $184 Million	MT
17/05	Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	MT

Erasca, Inc. Further Strengthens Business Leadership with Two Key Promotions

May 16, 2023 at 05:30 pm IST

Erasca, Inc. announced that David Chacko, M.D., previously chief financial officer of Erasca, has been promoted to the dual position of CFO and chief business officer, and Nik Chetwyn, Ph.D., previously senior vice president of operations of Erasca, has been promoted to chief operating officer, with each promotion being effective as of May 15, 2023.

Latest news about Erasca, Inc.

Erasca Closes Oversubscribed Share Offering to Raise $184 Million	22/05	MT
Erasca Acquires 2 Exclusive Worldwide Licenses for Preclinical RAS Programs	17/05	MT
Erasca Prices $160 Million Common Stock Offering	17/05	MT
Erasca, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05	CI
North American Morning Briefing : Powell Awaited -2-	03/04	DJ
Goldman Sachs Adjusts Erasca's Price Target to $7 From $6, Maintains Buy Rating	02/04	MT
Erasca, Inc. announced that it has received $45 million in funding	02/04	CI
Erasca, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	28/03	CI
Erasca, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/03	CI
Erasca, Inc. announced that it expects to receive $45 million in funding	27/03	CI
Capital One Initiates Erasca at Overweight Rating With $8 Price Target	11/03	MT
Erasca Enters Two Supply Deals With Novartis for Trametinib	14/02	MT
Erasca, Inc. Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials	14/02	CI
North American Morning Briefing : Boeing Drags -2-	08/01	DJ
Erasca, Inc. Receives FDA Fast Track Designation for Pan-RAF Inhibitor Naporafenib in Patients with Advanced NRAS-Mutated Melanoma	11/12	CI
ErascaCEO Bought Shares Worth $1,696,179, According to a Recent SEC Filing	07/12	MT
HC Wainwright Cuts Erasca Price Target to $8 From $10, Maintains Buy Rating	28/11	MT
Erasca Completes Dose Escalation in Phase 1 Thunderbbolt-1 Trial; Extends Cash Runway to 2026	28/11	MT
Erasca, Inc. Achieves Key Milestones for Naporafenib and ERAS-801 Programs and Extends Cash Runway	28/11	CI
Erasca, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
HC Wainwright Initiates Erasca at Buy Rating With $10 Price Target	11/23/11	MT
Erasca Shares Jump After CEO Stock Purchase Disclosed	10/23/10	MT
Erasca Insider Bought Shares Worth $2,026,000, According to a Recent SEC Filing	10/23/10	MT
Erasca Doses First Patient in Trial Assessing Naporafenib Plus Trametinib in Patients With RAS Q61X Solid Tumors	29/23/29	MT
Erasca, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11	CI

Chart Erasca, Inc.

Duration

Period

More charts

Company Profile

Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled a wholly owned or controlled RAS/MAPK pathway-focused pipeline in the industry, which is focused on modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes three clinical-stage programs, such as a pan-RAF inhibitor, an ERK inhibitor, and a central nervous system (CNS)-penetrant EGFR inhibitor, and additional discovery-stage programs targeting other key oncogenic drivers. Its lead product candidate is naporafenib, a pan-RAF inhibitor with the potential for patients with NRAS-mutated (NRASm) melanoma, RAS Q61X solid tumors, and other RAS/MAPK pathway-driven tumors.

Sector

Biotechnology & Medical Research

Calendar

07:30pm - American Society of Clinical Oncology Meeting - Abstract Number : TPS3178

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.52 USD

Average target price

5.375 USD

Spread / Average Target

+113.29%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ERASCA, INC.	+19.25%	69Cr
MODERNA, INC.	+43.36%	5.46TCr
IQVIA HOLDINGS INC.	-5.31%	3.99TCr
LONZA GROUP AG	+37.52%	3.88TCr
ICON PUBLIC LIMITED COMPANY	+14.75%	2.69TCr
CELLTRION, INC.	-12.56%	2.62TCr
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	1.88TCr
UNITED THERAPEUTICS CORPORATION	+25.12%	1.22TCr
BIO-TECHNE CORPORATION	+0.04%	1.22TCr
MEDPACE HOLDINGS, INC.	+26.04%	1.19TCr

Other Biotechnology & Medical Research